Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-05-02

FDA Approved: KUVAN — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approved BioMarin's supplemental application for KUVAN (sapropterin dihydrochloride) submitted by BioMarin Pharmaceutical Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KUVAN (Sapropterin dihydrochloride)

Snippet

SUPPL AP for KUVAN (SAPROPTERIN DIHYDROCHLORIDE)